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Abstract
Chronic pain is commonly co-morbid with a depressive or anxiety disorder. Objective of this study is to examine the
influence of depression, along with anxiety, on pain-related disability, pain intensity, and pain location in a large sample of
adults with and without a depressive and/or anxiety disorder. The study population consisted of 2981 participants with a
depressive, anxiety, co-morbid depressive and anxiety disorder, remitted disorder or no current disorder (controls). Severity
of depressive and anxiety symptoms was also assessed. In separate multinomial regression analyses, the association of
presence of depressive or anxiety disorders and symptom severity with the Chronic Pain Grade and location of pain was
explored. Presence of a depressive (OR = 6.67; P,.001), anxiety (OR = 4.84; P,.001), or co-morbid depressive and anxiety
disorder (OR = 30.26; P,.001) was associated with the Chronic Pain Grade. Moreover, symptom severity was associated with
more disabling and severely limiting pain. Also, a remitted depressive or anxiety disorder showed more disabling and
severely limiting pain (OR = 3.53; P,.001) as compared to controls. A current anxiety disorder (OR = 2.96; p,.001) and a co-
morbid depressive and anxiety disorder (OR = 5.15; P,.001) were more strongly associated with cardio-respiratory pain,
than gastro-intestinal or musculoskeletal pain. These findings remain after adjustment for chronic cardio respiratory illness.
Patients with a current and remitted depressive and/or anxiety disorder and those with more severe symptoms have more
disabling pain and pain of cardio-respiratory nature, than persons without a depressive or anxiety disorder. This warrants
further research.
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Introduction
Chronic pain is common in up to 70% of patients with
depressive and anxiety disorders [1–9]. Chronic pain and
depression most likely have a bidirectional association: depression
is a predictor of persistent pain and pain is a predictor of the
persistence of depression [1,3,10]. A possible explanation is that
impaired functioning caused by pain can lead to social isolation,
which in turn can lead to a negative effect on depressive
symptoms, and vice versa [11,12]. Furthermore, different brain
areas, such as the amygdala and hypothalamus, play a role in both
depression and pain [13,14]. Also, when depression and chronic
pain are co-morbid, recognition and treatment of depression are
less effective, as patients mostly only present their physical
complaints and receive treatment accordingly [1].
Most studies up to now have only considered the relationship of
pain with depression, whereas its association with anxiety disorders
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has been less examined. It is likely that the association of pain and
anxiety is equally important, as depression and anxiety commonly
appear together. Pain may cause feelings of anxiety, which in turn
can make one more sensitive to pain, with persistence of the pain
experience as a consequence [15]. Furthermore, anxiety disorders
and chronic pain share underlying cognitive and behavioural
processes, such as increased attention towards threat and anxious
avoidance of physical exertion [16,17]. Fear avoidance can play a
role in chronic pain, with the (acute) pain experience leading to
pain catastrophising and pain-related fear which in turn will lead
to greater disability and persistent pain experience [15]. There-
fore, we need more comprehensive insight by studying both
depression and anxiety in concert (separately and as co-morbid
problems) with pain [18–20]. Another reason to study the cross-
sectional relationship between depressive and anxiety disorders
and pain is that pain also has a negative impact on the prognosis of
psychopathology and psychiatric treatment outcome, with pain
leading to more treatment resistance [2,21–23]. Pain may be a
marker of a more difficult-to-treat disorder, and lead to a longer
time before remission [24].
Pain is a common presenting symptom in depression and
anxiety and several studies have explored this association for
specific pain symptoms, such as back pain [25–27] or neck pain
[27,28]. However, pain symptoms often occur in more than one
location and thus may be clustered; clustering of (medically
unexplained) physical symptoms was examined by Wessely et al.
[29], Nimnuan et al. [30], and Fink et al. [31]. These studies found
different clusters of pain symptoms, the most prominent being
musculoskeletal, gastro-intestinal, and cardio-respiratory pain.
Associations were found between depressive, but mostly anxiety
symptoms and cardio-respiratory pain, musculoskeletal pain and
gastro-intestinal pain. However, the strength of these associations
and the correlation with pain-related disability has not yet been
explored [32–34]. Therefore, this study will explore the association
of clustered locations of pain (musculoskeletal, gastro-intestinal,
and cardio-respiratory) with depression and anxiety, while taking
severity of pain and pain-related disability into account.
We aim to examine and compare the impact of current and
remitted depressive, anxiety and co-morbid disorders on different
pain-variables in a large sample of individuals with depressive
and/or anxiety disorders versus normal controls. We will explore if
severity of depressive or anxiety symptoms is associated with
severity of pain and pain-related disability, and whether these
associations are stronger for certain clustered pain locations. We
expect that not only a depressive disorder will have a strong
association with abovementioned pain-variables, but that an
anxiety disorder will show a comparably strong association, with




The present study used data from the Netherlands Study of
Depression and Anxiety (NESDA): an ongoing longitudinal cohort
study in which 2981 participants, recruited from the community,
general practice and secondary mental health care, are monitored
to investigate the long-term course and consequences of depressive
and anxiety disorders. Penninx et al. [35] provide a detailed
description of the NESDA study design and sampling procedures.
NESDA was designed to include patients with depressive and
anxiety disorders at different stages of development of their
disorder. In order to achieve this, participants were recruited from
the community, in primary care and in specialised mental health
care [35]. At baseline, healthy controls, persons with a prior
history, and persons with a current depressive and/or anxiety
disorder, between 18 and 65 years old, were included. The sample
was stratified for setting (community, primary care, and specialised
mental health). Furthermore, the sample includes a range of
psychopathology: from those without a depressive or anxiety
disorder (controls) to those with a current, first or recurrent (in the
past 6 months) depressive or anxiety disorder and those with a
remitted disorder (at baseline, a depressive and/or anxiety
disorder was diagnosed in the past, but no diagnoses were present
at 6 months before baseline). The disorders included dysthymia,
major depressive disorder, general anxiety disorder, panic
disorder, social phobia, and agoraphobia. Exclusion criteria were
not being fluent in Dutch and a primary diagnosis of psychotic,
obsessive compulsive, bipolar or severe addiction disorder. The
research protocol was approved by the Ethical Committee of
participating universities and written informed consent was
obtained from all participants. Interviews were conducted by
specially trained research staff.
The sample consists of 2329 persons with a current diagnosis of
depression (n = 396) or anxiety disorder (n = 543), a remitted
disorder (n = 628) and 652 persons without a history of depressive
and/or anxiety disorder and no current diagnosis of depression or
anxiety disorder. All 2981 participants were interviewed, by
specially trained clinical research staff, for depression and/or
anxiety in the baseline interview using the DSM IV based
Composite International Diagnostic Interview (CIDI, version 2.1),
a reliable and valid instrument for assessing depressive and anxiety
disorders [36].
The baseline measurement of NESDA, collected between
September 2004 and February 2007, was used for this study.
Next to the structured interview to assess mental health, self-report
questionnaires were used to assess physical health (such as chronic
disease, pain, and severity of mental health).
Measures
Pain assessment. Pain was assessed using the 7-item
Chronic Pain Grade (CPG) Scale by von Korff [37]. The CPG
is a reliable and valid instrument for chronic pain populations and
the general population [37,38]. The CPG is a good instrument for
measuring pain-related variables and for making a hierarchical
classification of pain intensity and pain-related disability. It has
good internal consistency (with a Cronbach’s alpha of 0.91) and
the item-total correlations are all high, ranging from .69 to .83.
The CPG grades (chronic) pain using pain intensity and pain-
related disability. Pain intensity is based on the mean of the
average, worst, and present pain on a scale of 0–100. Pain–related
disability is based on the mean of interference with usual activities,
work/household activities, and family/social activities on a scale of
0–100, and the number of days (0–180) one is unable to carry out
usual activities due to pain in the previous 6 months. To create 5
grades for chronic pain, the following calculations were used: pain
intensity was divided into low intensity (score ,50) and high
intensity (score $50). To calculate the score of pain-related
disability, an overall score of 0–6 was created by assigning 0–3
points for disability score (0–29 = 0; 30–49 = 1; 50–69 = 2; 70–
100 = 3) and adding 0–3 points for number of disability days (0–6
days = 0; 7–14 days = 1; 15–30 days = 2; .30 days = 3). With these
scores, 5 grades of chronic pain can be calculated:
grade 0 (no pain symptoms);
grade 1 (low pain intensity (,50) – low disability (,3 points));
grade 2 (high intensity ($50) – low disability (,3 points));
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grade 3 (high disability – moderately limiting (3–4 disability points,
regardless of intensity));
grade 4 (high disability – severely limiting (5–6 disability points,
regardless of intensity)).
Along with the CPG, we also assessed the specific pain location.
To locate the specific pain location, an inventory was made, with a
self-report questionnaire, of pain symptoms in the back, neck,
head, stomach, joints, chest, and face. Participants could report
one or more of these pain locations, and were asked which of these
pain locations bothered them the most in the last six months. We
then categorised these pain locations as musculoskeletal (back,
neck, head, joints, face), gastro-intestinal (stomach), and cardio
respiratory (chest) pain symptoms. Participants could report
multiple pain symptoms across the categories.
Depression and anxiety. The presence of a depressive or
anxiety disorder was established using the CIDI. In this study,
psychopathology profiles were made for each participant. A
participant either had no psychopathology (n = 652), a remitted
disorder (depression and/or anxiety) (n = 628), a current depres-
sive disorder (n = 396), a current anxiety disorder (n = 543) or a
current co-morbid depressive and anxiety disorder (n = 762) (in the
past 6 months).
In addition to this categorical approach of disorders (yes/no),
we also assessed severity of depressive and anxiety symptoms.
Severity of depressive symptoms was assessed with the Quick
Inventory of Depressive Symptomatology-Self-Report (QIDS-SR)
[39], in which no pain items are included. The QIDS-SR is the
shortened version of the self-rated Inventory of Depressive
Symptomatology (IDS-SR) [40] and is a 16-item questionnaire
with a range of 0 to 27 with high internal consistency (Cronbach’s
a = 0.86). A score of 0–5 refers to none to mild depressive
symptoms, a score of 6–10 refers to mild severity, a score of 11–15
refers to moderate severity, and a score of 16 or higher refers to
(very) severe depressive symptoms. Severity of anxiety symptoms
was assessed with the Beck Anxiety Inventory (BAI) [41], which
also does not include any pain items. The BAI is a 27-item
questionnaire ranging from 0 to 63 also with high internal
Table 1. Baseline characteristics of total NESDA sample (N = 2981).
N (%) Mean (SD)
Demographics
Female gender 1979 (66.4)
Age in years 41.9 (13.1)
Level of education Basic 199 (6.7)
Intermediate 1736 (58.2)
High 1046 (35.1)
Partner or married 2066 (69.3)
Psychopathology characteristics
No psychopathology 652 (21.9)
Remitted disorder 628 (21.0)
# of depressive episodes 1.73 (5.9)
Current depressive disorder 396 (13.3)
# of depressive episodes 10.29 (71.3)
Current anxiety disorder 543 (18.2)
Current depressive and anxiety disorder 762 (25.6)
# of depressive episodes 9.88 (72.6)
Severity of depression (QIDS)* None 1121 (37.6)
Mild 820 (27.5)
Moderate 627 (21.0)
(Very) Severe 374 (12.5)





Musculoskeletal chronic disease 648 (21.7)
Gastro-intestinal chronic disease 335 (11.2)
Cardio respiratory chronic disease 775 (26.0)
Antidepressant use 785 (26.4)
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consistency (Cronbach’s a = 0.92). A score of 0–9 refers to normal
severity, whereas a score of 10–18 refers to mild severity, a score of
18–29 refers to moderate severity, and a score higher than 29
refers to severe anxiety symptoms [42].
Covariates. Covariates were selected a priori based on
previous research on the association of depression and anxiety
with pain. Socio-demographic factors included gender, age, level
of education, and partner status. Furthermore, the presence of
chronic diseases was taken into account as a covariate. Based on
self-report during the initial interview, the presence of a chronic
disease was assessed. These chronic diseases were then categorised,
by a physician, into cardio respiratory disease (coronary heart
disease, angina pectoris, heart failure, chronic nonspecific lung
disease, stroke, hypertension), gastro-intestinal disease (diabetes,
(gastro-intestinal) ulcer, ulcerative colitis or Crohn’s disease, liver
cirrhosis, hepatitis) and musculoskeletal disease (arthritis, osteoar-
thritis, rheumatism). Because medication can have an analgesic
influence on pain, the use of antidepressants and other psycho-
tropic drugs were also selected as covariates. Also, the number of
depressive episodes was taken into account as a covariate.
Statistical Analyses. All statistical analyses were performed
in SPSS 19 for Windows. Descriptive analyses were used to assess
baseline characteristics across the total sample. To assess the
associations of type of disorder with the CPG, we used
multinomial logistic regression analyses. For the pain outcome
variable (the CPG) we used the group with no pain (CPG0) as a
reference category. For type of disorder, the healthy control group
without depression or anxiety was selected as a reference category.
In this analysis we controlled for all the covariates.
We used adjusted multinomial analyses to assess the association
of severity of depressive and anxiety symptoms with the outcome
variable CPG, with the lowest severity category as the reference
category.
Furthermore, we used four separate logistic regression analyses
to examine the association of depression and/or anxiety with the
outcome variable of location of pain (1. no pain, 2. musculoskeletal
pain (controlling for the presence of musculoskeletal disease), 3.
gastro-intestinal pain (controlling for the presence of gastro-
intestinal disease), and 4. cardio respiratory pain (controlling for
the presence of cardio respiratory disease)). Here also, having no
depressive or anxiety disorder was used as a reference category.
Results
Table 1 presents the baseline characteristics of the total
population. Of the total sample, 652 participants reported no
psychopathology, and slightly less participants (628) reported a
remitted depressive and/or anxiety disorder (with a mean of 1.73
depressive episodes). The least participants had a current
depressive disorder (with a mean of 10.29 depressive episodes),
followed by a current anxiety disorder. Most participants reported
a current comorbid depressive and anxiety disorder, with a mean
of almost 10 depressive episodes. 26.4% of the total sample used
antidepressant medication. Of the 2981 participants, 170 (5.7%)
reported no pain symptoms. Most participants (92.4%) reported
having musculoskeletal pain, followed by gastro-intestinal pain
(1432 participants), and cardio respiratory pain (764 participants).
Table 2 shows the pain characteristics, separated in no psycho-
pathology, remitted disorder, current depressive disorder, current
anxiety disorder, and current depressive and anxiety disorder. Of
the total sample and of each of the abovementioned groups, most
participants had low intensity and low pain-related disability
(CPG1), and pain of musculoskeletal origin. Especially when a
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participants report highly disabling and severely limiting pain
(CPG4).
Association of depression and/or anxiety with the CPG
Table 3 shows results from the adjusted multinomial logistic
regression analysis assessing the association of depression and/or
anxiety with the CPG. The results show a significant association
and the odds ratios (ORs) rise per CPG level. For all CPG levels,
the ORs were significantly elevated compared to the reference
group. Having a co-morbid depressive and anxiety disorder, as
compared to having no disorder, showed the strongest association
(OR = 30.26; 95% CI = 12.68–72.23). Also, when compared to
having no depression or anxiety, there is still a high odds of having
disabling pain symptoms when the depressive or anxiety disorder
is remitted (CPG1: OR = 1.87; 95% CI = 1.17–2.97; CPG4:
OR = 3.53; 95% CI = 1.67–7.43). However, the confidence
intervals do overlap. Therefore, four sensitivity analyses were
performed, each with an other psychopathology group (remitted
disorder, current depressive disorder, current anxiety disorder,
comorbid depression and anxiety) as a reference category, in order
to examine the possible differences in associations between pain
and various depressive and anxiety disorder categories (Tables 4–
7). With a current depressive disorder or anxiety disorder as
reference group, the results show no significant differences
between these disorders on the CPG. A current anxiety disorder
and a current depressive disorder also show no significant
difference with a remitted disorder. Only a co-morbid depressive
and anxiety disorder had a significantly higher association with the
CPG compared to a remitted, current depressive, and current
anxiety disorder. These findings were similar to those in the
analysis with the reference group of healthy controls. The
unadjusted results did not differ from the adjusted results.
Because the reference group for pain (CPG0) was small
(N = 170), another sensitivity analysis was conducted where
CPG0 and CPG1 were combined to form the reference category
(Table 8). This analysis showed that the association between type
of disorder and CPG mostly remains: as can be seen in table 8, all
associations became less strong after combining CPG0 and CPG1
as a reference category, but remained significant.
Association of severity of depressive and anxiety
symptoms with the CPG
Table 9 shows the association of the severity of depressive
symptoms (as measured with the QIDS) and anxiety symptoms (as
measured with the BAI) with the CPG. Similar to the main
finding, as the severity of the depressive symptoms increases, the
odds of having highly disabling and severely limiting pain increases
as well. The same accounts for the association between severity of
anxiety symptoms and the CPG. The unadjusted results did not
differ from the adjusted results.
Table 3. Associations of presence of current depressive disorder, current anxiety disorder, current co-morbid depression and
anxiety and remitted depression or anxiety with the Chronic Pain Grade, with no depression and/or anxiety disorder as a reference
category.
CPG1a,b CPG2a,b CPG3a,b CPG4a,b
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
No psychopathology reference reference reference reference
Remitted depression/anxiety 1.87 (1.17–2.97)* 3.45 (2.02–5.87)** 3.49 (1.81–6.73)** 3.53 (1.67–7.43)*
Depression current 1.35 (0.72–2.55) 3.53 (1.76–7.08)** 7.14 (3.28–15.54)** 6.67 (2.81–15.88)**
Anxiety current 2.10 (1.25–3.54)* 4.06 (2.26–7.30)** 5.15 (2.57–10.31)** 4.84 (2.22–10.57)**
Co-morbid depression and anxiety current 3.13 (1.56–6.25)* 10.18 (4.87–21.26)** 19.72 (8.77–44.35)** 30.26 (12.68–72.23)**
*p,.05;
**p,.001.
areference category is no pain.
badjusted for age, gender, level of education, partner status, antidepressant use, use of other psychotropic drugs, chronic diseases, and number of depressive episodes.
doi:10.1371/journal.pone.0106907.t003
Table 4. Associations of presence of current depressive disorder, current anxiety disorder, current co-morbid depression and
anxiety and remitted depression or anxiety with the Chronic Pain Grade, with remitted disorder as a reference category.
CPG1a,b CPG2a,b CPG3a,b CPG4a,b
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Remitted depression/anxiety reference reference reference reference
No psychopathology .54 (.34–.85)* .29 (.17–.50)** .29 (.15–.55)** .28 (.14–.60)*
Depression current .72 (.39–1.36) 1.03 (.52–2.01) 2.04 (.98–4.25) 1.89 (.85–4.20)
Anxiety current 1.13 (.64–2.00) 1.18 (.64–2.18) 1.47 (.74–2.94) 1.37 (.65–2.91)
Co-morbid depression and anxiety current 1.68 (.84–3.36) 2.95 (1.43–6.09)* 5.65 (2.61–12.22)** 8.58 (3.84–19.21)**
*p,.05;
**p,.001.
areference category is no pain.
badjusted for age, gender, level of education, partner status, antidepressant use, use of other psychotropic drugs, chronic diseases, and number of depressive episodes.
doi:10.1371/journal.pone.0106907.t004
Depression, Anxiety and Pain
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Because the reference group for pain (CPG0) was small
(N = 170), a sensitivity analysis was conducted where CPG0 and
CPG1 were combined to form the reference category (table 10).
This analysis showed that the association found between severity
of depressive and anxiety symptoms and CPG mostly remains,
with more severe depressive or anxiety symptoms being more
strongly associated with more disabling and limiting pain, when
CPG0 and CPG1 were combined to have a larger reference
group. Here also, all associations were less strong, with some
associations (especially the association of severe anxiety symptoms
with the CPG2 and CPG4) remaining statistically significant, while
other associations (e.g. the association of mild and moderate
anxiety symptoms with CPG3) becoming non-significant.
Association of depression and/or anxiety with
musculoskeletal, gastro-intestinal, and cardio respiratory
pain symptoms
Table 11 shows the multinomial logistic regression analyses
assessing the association of depression and/or anxiety with three
clustered pain locations. For those with pain, the highest ORs are
seen in co-morbid depression and anxiety. The ORs for
musculoskeletal pain range from 2.28 (95% CI = 1.53–3.42) for
a depressive or anxiety disorder in remission to 3.88 (95%
CI = 2.33–6.47) for a co-morbid depressive and anxiety disorder.
For gastro-intestinal pain, the ORs range from 1.40 (95%
CI = 1.10–1.78) for a depressive or anxiety disorder in remission
to 3.31 (95% CI = 2.57–4.27) for a co-morbid depressive and
anxiety disorder. Cardio respiratory pain shows a range in ORs
from 1.74 (95% CI = 1.27–2.40) for a depressive or anxiety
disorder in remission to 5.15 (95% CI = 3.80–6.98) for co-morbid
depressive and anxiety disorder. The unadjusted results did not
differ from the adjusted results.
Discussion
The high proportion of participants with anxiety and depressive
disorders in this study reflects the sampling strategy for including
sufficient numbers of respondents to examine individuals at
different stages of development and severity of depression and
anxiety. This study demonstrates considerable associations be-
tween presence of depressive and anxiety disorders (current and
remitted) and symptom severity with different pain dimensions,
namely pain-related disability, pain intensity, and the location of
pain symptoms (musculoskeletal, gastro-intestinal, and cardio
respiratory).
Presence and severity of depressive or anxiety disorder
Our results show that having a mood or anxiety disorder
increases the odds of highly disabling and severely limiting pain.
Also, the severity of the depressive and anxiety symptoms are
significantly associated with pain-related disability and limiting
Table 5. Associations of presence of current depressive disorder, current anxiety disorder, current co-morbid depression and
anxiety and remitted depression or anxiety with the Chronic Pain Grade, with current depressive disorder as a reference category.
CPG1a,b CPG2a,b CPG3a,b CPG4a,b
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Depression current reference reference reference reference
No psychopathology .74 (.39–1.40) .28 (.14–.57)** .14 (.0–31)** .15 (.06–.36)**
Remitted depression/anxiety 1.38 (.74–2.59) .98 (.50–1.91) .49 (.24–1.02) .53 (.24–1.17)
Anxiety current 1.56 (.79–3.05) 1.15 (.56–2.35) .72 (.34–1.54) .73 (.32–1.65)
Comorbid depression and anxiety current 2.31 (1.10–4.85)* 2.88 (1.34–6.21)* 2.76 (1.25–6.09)* 4.53 (2.00–10.30)**
*p,.05;
**p,.001.
areference category is no pain.
badjusted for age, gender, level of education, partner status, antidepressant use, use of other psychotropic drugs, chronic diseases, and number of depressive episodes.
doi:10.1371/journal.pone.0106907.t005
Table 6. Associations of presence of current depressive disorder, current anxiety disorder, current co-morbid depression and
anxiety and remitted depression or anxiety with the Chronic Pain Grade, with current anxiety disorder as a reference category.
CPG1a,b CPG2a,b CPG3a,b CPG4a,b
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Anxiety current reference reference reference reference
No psychopathology .48 (.28–.80)* .25 (.14–.44)** .19 (.10–.39)** .21 (.10–.45)**
Remitted depression/anxiety .89 (.450–1.57) .85 (.46–1.57) .68 (.34–1.35) .73 (.34–1.54)
Depression current .64 (.33–1.26) .87 (.43–1.78) 1.39 (.65–2.97) 1.38 (.61–3.13)
Comorbid depression and anxiety current 1.49 (.72–3.06) 2.51 (1.18–5.30)* 3.83 (1.74–8.42)* 6.25 (2.76–14.15)**
*p,.05;
**p,.001.
areference category is no pain.
badjusted for age, gender, level of education, partner status, antidepressant use, use of other psychotropic drugs, chronic diseases, and number of depressive episodes.
doi:10.1371/journal.pone.0106907.t006
Depression, Anxiety and Pain
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pain, with more severe symptoms having higher odds for highly
disabling and severely limiting pain.
Depressive and anxiety disorders may add to pain as they
increase the likelihood of social isolation, increased attention
towards threat and avoidance of physical exertion [11,12,16,17].
Depression and anxiety disorders also share the same pathophys-
iological pathways as pain [43–45]. They facilitate the central
modulation of the pain response, in the periaqueductal gray,
amygdala, and hypothalamus [1,13,14], and when deficits occur in
these areas, modulation of signals from the body are disturbed,
leading to a more severe experience of pain. Although these brain
areas all play a role in depression, anxiety, and pain, not every
individual responds the same to pain stimuli [46–48]. Some
individuals are more sensitive to pain than others. The use of EEG
may help in identifying neuronal markers for sensitivity to pain
[46], and whether there are differences between depressive and
anxious individuals. Furthermore, depression and anxiety induce
stress and increases the production of pro-inflammatory cytokines
[49–51], which may increase pain [52,53]. The finding showing
higher pain-related disability in co-morbid depression and anxiety
in our study is similar to findings from the STAR*D studies [54–
56].
Depressive or anxiety disorder in remission
Regarding the association of a remitted disorder and pain, we
expected persons with remitted depression or anxiety to have
similar pain symptoms as controls without depression or anxiety.
However, this is not the case. Persons with a remitted depressive or
anxiety disorder still showed high odds on the pain outcomes when
compared to those that have no such disorder. This is remarkable,
because this means that having a remitted disorder is not the same
as having no disorder with regards to pain. This raises several
questions.
First, pain symptoms may be residual symptoms in depressive
and anxiety disorder. This finding may suggest that pain in
patients with remitted depressive or anxiety disorder might be
indicative of a risk for recurrence, as disability in life (e.g. disability
to fulfil his or her role at home) is an important risk factor for the
recurrence of anxiety disorders [57], and our results show that
those with a remitted diagnosis still have high odds of having pain
symptoms and pain-related disability.
Another explanation for the high odds of pain symptoms in
remitted depression or anxiety might be that treatment, if it was
provided, for the depressive or anxiety disorder is not effective for
pain symptoms, or treatment should be different when pain is co-
morbid with the depressive or anxiety disorder. For example, it has
been suggested that patients with depression and pain are a
Table 7. Associations of presence of current depressive disorder, current anxiety disorder, current co-morbid depression and
anxiety and remitted depression or anxiety with the Chronic Pain Grade, with comorbid depressive- and anxiety disorder as a
reference category.
CPG1a,b CPG2a,b CPG3a,b CPG4a,b
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Comorbid depression and anxiety current reference reference reference reference
No psychopathology .32 (.16–.64)* .10 (.05–.21)** .05 (.02–.11)** .03 (.01–.08)**
Remitted depression/anxiety .60 (.30–1.20) .34 (.16–.70)* .18 (.08–.38)** .12 (.05–.26)**
Depression current .43 (.21–.91)* .35 (.16–.75)* .36 (.16-.80)* .22 (.10–.50)**
Anxiety current .67 (.33–1.39) .40 (.19–.85)* .26 (.12–.57)* .16 (.07–.36)**
*p,.05;
**p,.001.
areference category is no pain.
badjusted for age, gender, level of education, partner status, antidepressant use, use of other psychotropic drugs, chronic diseases, and number of depressive episodes.
doi:10.1371/journal.pone.0106907.t007
Table 8. (Results from sensitivity analysis, with CPG0 and CPG1 combined) Associations of presence of current depressive disorder,
current anxiety disorder, current co-morbid depression and anxiety and remitted depression or anxiety with the Chronic Pain
Grade, with no depression and/or anxiety disorder as a reference category.
CPG2a,b CPG3a,b CPG4a,b
OR (95% CI) OR (95% CI) OR (95% CI)
No psychopathology reference reference reference
Remitted depression/anxiety 1.99 (1.45–2.73)** 2.01 (1.22–3.30)* 2.03 (1.10–3.73)*
Depression current 2.78 (1.93–4.01)** 5.61 (3.39–9.29)** 5.23 (2.77–9.85)**
Anxiety current 2.09 (1.50–2.92)** 2.65 (1.61–4.35)** 2.48 (1.34–4.59)*
Comorbid depression and anxiety current 3.63 (2.61–5.04)** 7.01 (4.38–11.23)** 10.72 (6.07–18.96)**
*p,.05;
**p,.001.
areference category is no pain.
badjusted for age, gender, level of education, partner status, antidepressant use, use of other psychotropic drugs, chronic diseases, and number of depressive episodes.
doi:10.1371/journal.pone.0106907.t008
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distinctively other group of patients than those with depression
without pain, with the former having a focus on health and the
latter having a focus on a negative view of the self [58,59]. If that is
the case, the treatment should be different for depressive disorder
with pain and depressive disorder without pain. The same could
possibly apply to patients with an anxiety disorder with or without
pain. This finding warrants further research, to examine if having
a depressive or anxiety disorder in remission may be a possible risk
factor for subsequent long lasting chronic pain.
Pain location
Of the total sample, 92.4% reported pain symptoms of
musculoskeletal nature, followed by 48% reporting gastro-intesti-
nal pain and 25.6% of cardio respiratory pain. Because
musculoskeletal pain has by far the highest prevalence in this
study, we expected that this pain location would have the highest
association with depression and anxiety. However, this expectation
was not confirmed. Our findings show that those with a current
depressive disorder or a remitted depressive or anxiety disorder
have high odds for having musculoskeletal pain, but the odds for
having pain of cardio respiratory origin are also large when
compared to having no depressive or anxiety disorder. Further-
more, persons having a current anxiety or co-morbid depressive
and anxiety disorder show high odds for having cardio respiratory
pain. These findings remain after adjustment for chronic cardio
respiratory illness.
In a review by Celano & Huffman [60], depressive disorder was
associated with cardiac disease, such as coronary artery disease.
This also applies to anxiety which appears to be a risk factor for
coronary heart disease and cardiac mortality [61]. The finding
Table 9. Association of severity of depressive symptoms and anxiety symptoms with the Chronic Pain Grade.
CPG1a,b CPG2a,b CPG3a,b CPG4a,b
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
QIDSb None reference reference reference reference
Mild 2.59 (1.55–4.34)** 3.72 (2.13–6.49)** 3.99 (2.13–7.49)** 4.05 (1.99–8.23)**
Moderate 1.10 (0.59–2.02) 1.56 (.91–3.40) 3.32 (1.62–6.80)* 2.91 (1.31–6.48)*
(Very) Severe 1.11 (.43–2.87) 2.18 (.81–5.87) 4.66 (1.65–13.16)* 7.93 (2.70–23.35)**
BAIc Normal reference reference reference reference
Mild 1.76 (.59–12.51) 2.41 (1.36–4.29)* 2.66 (1.42–4.97)* 3.07 (1.54–6.12)*
Moderate 2.23 (.99–5.03) 4.22 (1.82–9.79)* 3.89 (1.60–9.45)* 6.69 (2.66–16.84)**
Severe 2.73 (1.02–3.02)* 6.70 (1.44–31.20)* 8.29 (1.73–39.59)* 13.32 (2.73–64.97)*
*p,.05;
**p,.001.
areference category is no pain.
badjusted for age, gender, level of education, partner status, chronic diseases, antidepressant use, use of other psychotropic drugs, number of depressive episodes, and
severity of anxiety symptoms.
cadjusted for age, gender, level of education, partner status, chronic diseases, antidepressant use, use of other psychotropic drugs, number of depressive episodes, and
severity of depressive symptoms.
doi:10.1371/journal.pone.0106907.t009
Table 10. (Results of sensitivity analysis, with CPG0 and CPG1 combined) Association of severity of depressive symptoms and
anxiety symptoms with the Chronic Pain Grade.
CPG2a,b CPG3a,b CPG4a,b
OR (95% CI) OR (95% CI) OR (95% CI)
QIDSb None reference reference reference
Mild 1.55 (1.18–2.02)* 1.65 (1.11–2.46)* 1.67 (1.00–2.80)*
Moderate 1.67 (1.21–2.33)* 3.14 (2.04–4.83)** 2.75 (1.58–4.78)**
(Very) Severe 2.05 (1.36–3.09)* 4.37 (2.61–7.33)** 7.42 (4.08–13.649)**
BAIc Normal reference reference reference
Mild 1.42 (1.09–1.85)* 1.57 (1.09–2.24)* 1.81 (1.14–2.87)*
Moderate 1.99 (1.44–2.75)** 1.83 (1.19–2.81)* 3.15 (1.91–5.19)**
Severe 2.59 (1.63–4.13)** 3.12 (1.86–5.53)** 5.16 (2.83–9.41)**
*p,.05;
**p,.001.
areference category is no pain.
badjusted for age, gender, level of education, partner status, chronic diseases, antidepressant use, use of other psychotropic drugs, number of depressive episodes, and
severity of anxiety symptoms.
cadjusted for age, gender, level of education, partner status, chronic diseases, antidepressant use, use of other psychotropic drugs, number of depressive episodes, and
severity of depressive symptoms.
doi:10.1371/journal.pone.0106907.t010
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that anxiety shows such high odds for cardio respiratory pain
symptoms, even when we controlled for cardio respiratory disease,
could be due to the fact that anxious patients with chest pain are
more sensitive to bodily sensations [62]; in that case, the
experience of pain would be centrally modulated in such a way
as to elevate the odds for experiencing pain. However, another
explanation might be possible as well; stress induced anxiety has
an elevating effect on cytokines [49], and elevated cytokines lead to
pain symptoms. This might explain our findings.
In the STAR*D study, depressed patients (with less sleep quality
and sympathetic arousal) showed an association with higher
cardiac risk, which may be similar to our findings [63] whereby
having a depressive disorder had higher odds for having cardio
respiratory pain when compared to having no depressive or
anxiety disorder. Even when we controlled for having a chronic
disease of cardio respiratory origin, the association remained
strong and significant. Previous research showed that having a
mental illness is a possible risk factor for cardiovascular disease
[64,65]. Our finding that a depression/anxiety, whether or not in
remission, shows a strong association with cardiac pain is worth
exploring in further longitudinal research to explore a possible
causal relation of depression and/or anxiety (current or in
remission) with cardiac disease, of which cardio respiratory pain
might be an early indicator.
Strengths of the study
A strength of this study is the large sample size. Also, because
patients with a depressive or anxiety disorder often report pain in
multiple locations, the categorisation of pain locations makes these
results clinically relevant and widely applicable. Moreover, this
study not only examines the association of pain with depressive or
anxiety disorder, but also with co-morbid depression and anxiety,
as well as with remitted disorders. Additionally, in the analyses of
the pain symptoms, the no pain group was the reference category
which is new compared to earlier studies that compared low pain
with high pain – which is subject to interpretation bias as pain is a
subjective experience. In our study, we had a healthy control
group with no pain in which better contrasts could be made with
those who had pain.
Limitations
This study also has some limitations. First, it is not possible to
make inferences about causality because this was a cross-sectional
observational study. Second, some of the subgroups of our sample
were smaller than the other groups, such as those with no pain
symptoms (CPG0, N = 170). However, a sensitivity analysis
revealed that the association between severity of depressive and
anxiety symptoms and CPG mostly remains, with more severe
depressive or anxiety symptoms being more strongly associated
with more disabling and limiting pain when CPG0 and CPG1
were combined to have a larger reference group. Therefore, these
associations can be considered valid and of clinical relevance as
they indicate a clear difference in association with depression or
anxiety between patients with and without pain. Another possible
limitation is the self-reporting of physical illness, which might lead
to overreporting or underreporting of chronic physical illness;
however, a study by Kriegsman et al. [66] shows that patients
report their physical illness fairly accurately when compared to the
reports of their general practitioner, even when taking depressive
symptomatology into account. Furthermore, no information was
available whether a physical illness was organic or functional,
which may have its effect on pain. For example, individuals with
an organic disease describe their pain as consistent, whereas those
without an organic disease describe their pain as variable and
diffuse [67]. Also, PTSD has been linked to increased risk for pain
[68,69]. Therefore, future research that examines the association
of anxiety disorders with pain should also include PTSD.
Conclusion
This study shows that depressive and anxiety disorders have a
similar and very strong association with the CPG (which includes
pain-related disability and pain intensity) and musculoskeletal
pain, cardio respiratory pain, and gastro-intestinal pain compared
to a control group without depressive or anxiety disorder.
Depression and anxiety share the same pathophysiological
pathways as pain and can have a reciprocal effect on each other,
which could explain these associations. Moreover, even a remitted
disorder has a strong association with pain. This might mean that
patients with depression or anxiety and pain are a different group
and need different treatment than patients that do not have pain
accompanying their depression or anxiety. Depression and anxiety
also have a strong association with cardio respiratory pain, and this
association remained after correction for cardiovascular or
respiratory illness. This strong association between depression/
anxiety (current or in remission) with cardio respiratory pain is an
interesting finding, which warrants further longitudinal research to
examine a possible causal relation of cardiac pain and a mental
disorder (current or in remission) with cardiac disease.
Table 11. Associations of remitted psychopathology, current depressive disorder, current anxiety disorder, and current co-morbid
depression and anxiety with pain location, with no depression and/or anxiety as reference category.
No paina Musculoskeletala Gastro-intestinala Cardio respiratorya
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
No psychopathology reference reference reference reference
Remitted depression/anxiety .47 (.30–.75)* 2.28 (1.53–3.42)** 1.40 (1.10–1.78)* 1.74 (1.27–2.40)*
Depression current .52 (.28–.97)* 2.64 (1.53–4.56)** 2.43 (1.84–3.22)** 2.63 (1.86–3.70)**
Anxiety current .39 (.24–.66)** 2.29 (1.49–3.51)** 2.08 (1.61–2.68)** 2.96 (2.16–4.04)**
Co-morbid depression and anxiety current .19 (.10–.38)** 3.88 (2.33–6.47)** 3.31 (2.57–4.27)** 5.15 (3.80–6.98)**
*p,.05;
**p,.001.
a = adjusted for age, gender, level of education, partner status, antidepressant use, use of other psychotropic drugs, number of depressive episodes, and chronic
disease.
doi:10.1371/journal.pone.0106907.t011
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